NEW YORK (GenomeWeb News) — Ciphergen Biosystems today said it has struck an agreement with the Ohio State University Research Foundation to develop and validate a test to help detect the blood disease thrombotic thrombocytopenic purpura.
The partnership aims to discover a clinical diagnostic test that can “rapidly detect” deficiencies in the enzyme activity associated with the disorder, commonly called TTP, which affects blood coagulation.
Under the agreement, Ciphergen will work with OSURF to develop an assay to measure enzyme and antibody inhibition activity that they will test together in a series of multi-center studies.
Ciphergen CSO Eric Fung said it will use a SELDI-based test for “accurately measuring the product of enzymatic chain reaction that underlies the disease” in order to help doctors manage the disease and the effects of treatment.
Financial terms of the agreement were not released.